As of the most recent data (September 2020), PTI shows a common stock of $52K. That compares with $51K in the prior-year period — up 2.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PTI's common stock is now $52K (was $51K) — a 2.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Proteostasis Therapeutics is outperforming or lagging.

Tracking PTI's common stock over time shows whether Proteostasis Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $52K That compares with $51K in the prior-year period — up 2.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Proteostasis Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $52K) with ownership activity and broader fundamentals.

Proteostasis Therapeutics's common stock is $52K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.